TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17179058

Group type: EXPERIMENTAL
Intervention: Usual care plus an informational brochure
Number of subjects: 781

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 781
Study: 12666320

Group type: EXPERIMENTAL
Intervention: Cancer screening programs
Number of subjects: 0
Study: 11139971

Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation (5, 10, 20, and 40 mA for 2 ms)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonstimulated complexes
Number of subjects: 77
Study: 8976803

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy plus calcium (Prempak C or Premarin 0.625 mg with 1 g calcium daily)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Calcium alone (1 g calcium daily)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 116
Study: 1309303

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) administered at 75 mg/m2 in 3-week cycles
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Less conventional schedules of cisplatin (exact dosages not specified)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) total dose of 450 mg/m2 across all groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) administration
Number of subjects: 60
Study: 6373830

Group type: EXPERIMENTAL
Intervention: EMG biofeedback (N = 70)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Relaxation training (N = 32)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cognitive structure measure
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mixed headache patients
Number of subjects: 102
Study: 29667066

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 mg
Number of subjects: 0
Study: 25773465

Group type: EXPERIMENTAL
Intervention: 4.6% menthol gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.5% menthol gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10.0% menthol gel
Number of subjects: 10
Study: 25576682

Group type: EXPERIMENTAL
Intervention: Higher resting heart rate (HR) ≥70 bpm in younger patients
Number of subjects: 327

Group type: COMPARATOR
Intervention: Lower resting heart rate (HR) <70 bpm in younger patients
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Higher resting heart rate (HR) in older patients
Number of subjects: 327

Group type: COMPARATOR
Intervention: Lower resting heart rate (HR) in older patients
Number of subjects: 327
Study: 25104263

Group type: COMPARATOR
Intervention: FC2
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Woman's Condom
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: VA wow
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cupid
Number of subjects: 600
Study: 21903710

Group type: EXPERIMENTAL
Intervention: Yoga (asana, pranayam, and meditation) for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no yoga)
Number of subjects: 0
Study: 17483128

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Non-users of digitalis
Number of subjects: 7329
Study: 17033530

Group type: EXPERIMENTAL
Intervention: 25 to 75 g/day milk-based fortified spreads
Number of subjects: 126

Group type: COMPARATOR
Intervention: Unsupplemented controls (0 to 5 g FS)
Number of subjects: 126
Study: 15208230

Group type: EXPERIMENTAL
Intervention: EMD‐aide
Number of subjects: 149

Group type: COMPARATOR
Intervention: 4Hs+4Ts
Number of subjects: 149
Study: 10710119

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/day)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/day) + Bezafibrate (400 mg/day)
Number of subjects: 454
Study: 9094876

Group type: EXPERIMENTAL
Intervention: High glycogen (HG) treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low glycogen (LG) treatment
Number of subjects: 8
Study: 8386421

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium eye drops
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium eye drops and astemizole combined
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium alone or combined
Number of subjects: 207

Group type: COMPARATOR
Intervention: Astemizole alone
Number of subjects: 207
Study: 3092661

Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms twice daily)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 93
Study: 28332886

Group type: EXPERIMENTAL
Intervention: Turbuhaler®
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Spiromax®
Number of subjects: 516
Study: 27353456

Group type: EXPERIMENTAL
Intervention: Conscious sedation
Number of subjects: 88
Study: 23718572

Group type: EXPERIMENTAL
Intervention: 4 g of FIB
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 unit of apheresis PLTs
Number of subjects: 20
Study: 22854310

Group type: EXPERIMENTAL
Intervention: Baclofen (titrated up to 60 mg daily or maximum tolerated dose, 48 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (48 days)
Number of subjects: 12
Study: 20044530

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril plus indapamide for those without contraindications)
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6105
Study: 17594201

Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg with Al-Mg antacid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered 2 hours after Al-Mg antacid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered 4 hours after Al-Mg antacid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered 4 hours before Al-Mg antacid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered 2 hours before Al-Mg antacid
Number of subjects: 20
Study: 16170978

Group type: EXPERIMENTAL
Intervention: Colgate MicroSonic battery-powered toothbrush
Number of subjects: 39

Group type: COMPARATOR
Intervention: Oral-B Indicator manual toothbrush
Number of subjects: 39
Study: 11781970

Group type: EXPERIMENTAL
Intervention: Ni-Cr-Be, chemically etched
Number of subjects: 63

Group type: COMPARATOR
Intervention: Au-Pd, airborne particle-abraded and tin-plated
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Au-Pd, airborne particle-abraded and treated with Alloy Primer
Number of subjects: 63
Study: 9264478

Group type: EXPERIMENTAL
Intervention: Invasive treatment (PTCA or CABG)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 1008
Study: 8497491

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (FOC) capsules (15 x 1 g/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (PO) capsules (15 x 1 g/d)
Number of subjects: 35
Study: 2433409

Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 232

Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 232

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 232
Study: 28884969

Group type: EXPERIMENTAL
Intervention: New procaterol dry powder inhaler (20 μg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Approved procaterol dry powder inhaler (20 μg)
Number of subjects: 16
Study: 27443162

Group type: EXPERIMENTAL
Intervention: Mixed model of dose estimates based on current and prior INRs
Number of subjects: 556

Group type: COMPARATOR
Intervention: GIFT algorithm (based on current INR)
Number of subjects: 556
Study: 23272667

Group type: EXPERIMENTAL
Intervention: Invitation group (n=156)
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: Opportunistic group (n=179)
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: Inactive participants (51.5% of screened)
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: Healthy participants subgroup (n=143)
Number of subjects: 1896
Study: 21515899

Group type: EXPERIMENTAL
Intervention: AFO set at 5° plantarflexion
Number of subjects: 8

Group type: COMPARATOR
Intervention: AFO set at 5° dorsiflexion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AFO set at neutral alignment
Number of subjects: 8
Study: 18473867

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a provisional GP IIb/IIIa inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urgent PCI
Number of subjects: 0
Study: 16433897

Group type: EXPERIMENTAL
Intervention: Intravenous heroin administration (67-100-150% of the regular heroin maintenance dose, max single dose 450 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heroin inhalation (67-100-150% of the regular heroin maintenance dose, max single dose 450 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (inhaling and injecting)
Number of subjects: 20
Study: 12869165

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10674593

Group type: EXPERIMENTAL
Intervention: Meclizine (50 mg pretreatment)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343

Group type: COMPARATOR
Intervention: No drug (no pretreatment)
Number of subjects: 343
Study: 9295240

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study: 8365603

Group type: EXPERIMENTAL
Intervention: 105-cm polyurethane feeding tubes
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 125-cm polyurethane feeding tubes
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 145-cm polyurethane feeding tubes
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All tube lengths
Number of subjects: 45
Study: 2821397

Group type: EXPERIMENTAL
Intervention: Intravenous CMV immune globulin
Number of subjects: 59

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 59
Study: 31963773

Group type: EXPERIMENTAL
Intervention: NAT-FM+TAU
Number of subjects: 160

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 160
Study: 29242937

Group type: EXPERIMENTAL
Intervention: Pazopanib plus paclitaxel
Number of subjects: 106

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 106
Study: 27522394

Group type: EXPERIMENTAL
Intervention: Once-daily fixed combination (ODFC) of perindopril 10mg, indapamide 2.5mg, amlodipine 5 or 10mg, and atorvastatin 20mg
Number of subjects: 305

Group type: COMPARATOR
Intervention: Free-drug combination (FDC) of the 3 antihypertensive agents plus atorvastatin 20mg
Number of subjects: 305
Study: 26635011

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study: 23557931

Group type: EXPERIMENTAL
Intervention: Longitudinal exposure to mycophenolic acid (MPA)
Number of subjects: 490
Study: 20964767

Group type: EXPERIMENTAL
Intervention: 0.5 ml·kg(‐1) of local anesthetic solution
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.75 ml·kg(‐1) of local anesthetic solution
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.0 ml·kg(‐1) of local anesthetic solution
Number of subjects: 45
Study: 17935144

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 353

Group type: COMPARATOR
Intervention: Education control condition
Number of subjects: 353
Study: 21679304

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg (titrated to 20 or 5 mg after 4 weeks)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 16194647

Group type: EXPERIMENTAL
Intervention: Clinical Nurse Specialist (CNS)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control
Number of subjects: 620
Study: 11883964

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation of the mandibular condyle
Number of subjects: 54
Study: 9883917

Group type: EXPERIMENTAL
Intervention: Hands poised method
Number of subjects: 5471

Group type: COMPARATOR
Intervention: Hands on method
Number of subjects: 5471
Study: 8039534

Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg capsule) after a full meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg capsule) after a full meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Itraconazole (100 mg capsule) on an empty stomach
Number of subjects: 24

Group type: COMPARATOR
Intervention: Itraconazole (100 mg capsule) after a light meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluconazole (100 mg capsule) on an empty stomach
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluconazole (100 mg capsule) after a light meal
Number of subjects: 24
Study: 3043994

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg b.i.d.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30115530

Group type: EXPERIMENTAL
Intervention: Topical pirfenidone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-adherent gauze (Control)
Number of subjects: 24
Study: 26720746

Group type: EXPERIMENTAL
Intervention: Telemedicine deployment at all hospitals
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Telemedicine deployment at outer-ring hospitals only
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: No telemedicine deployment
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Central physician location with partial telemedicine deployment
Number of subjects: 121
Study: 25515056

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intravenous Immunoglobulin (IVIg)
Number of subjects: 64
Study: 23565835

Group type: EXPERIMENTAL
Intervention: Brief health education counselling from nurses, a health education booklet, a 'no smoking' sticker, and a telephone reminder one week later.
Number of subjects: 1483

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1483
Study: 20538692

Group type: EXPERIMENTAL
Intervention: Intravenous MgSO4 infusion (80 mmol in 500 mL normal saline per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (500 mL normal saline per day)
Number of subjects: 0
Study: 19001531

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (intensified structured counseling between patient and pharmacist)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard counseling (control group)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (intervention group)
Number of subjects: 410
Study: 16946665

Group type: COMPARATOR
Intervention: Surgical treatment preference among White patients (55%)
Number of subjects: 2323

Group type: COMPARATOR
Intervention: Surgical treatment preference among White patients (46%)
Number of subjects: 2323

Group type: COMPARATOR
Intervention: Randomization rates among Black IDH patients (46%)
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Treatment preference (unsure) for IDH patients
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Treatment preference (surgical) for IDH patients
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Treatment preference (unsure) for SpS/DS patients
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Treatment preference (surgical) for SpS/DS patients
Number of subjects: 2323
Study: 14557432

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (500 IU)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin D (200 IU)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Prolonged critical illness (compared to matched controls)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Time in intensive care
Number of subjects: 22
Study: 10750207

Group type: EXPERIMENTAL
Intervention: Training alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Training plus ongoing telephone support
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no training or support)
Number of subjects: 84
Study: 9016145

Group type: EXPERIMENTAL
Intervention: Rinsing enteral delivery sets with tap water before formula addition
Number of subjects: 23

Group type: COMPARATOR
Intervention: No rinsing of enteral delivery sets before formula addition
Number of subjects: 23
Study: 2028125

Group type: EXPERIMENTAL
Intervention: Non-parametric estimator of prevalence of chronic graft-versus-host disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Markov and semi-Markov models
Number of subjects: 0
Study: 6424228

Group type: EXPERIMENTAL
Intervention: Low-lactose milk (500 ml)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-lactose milk (250 ml)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Regular skim milk
Number of subjects: 35
Study: 29992524

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Baseline late HMR
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 123I‐mIBG imaging
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Improvement in late HMR
Number of subjects: 121
Study: 29500103

Group type: EXPERIMENTAL
Intervention: Bilateral discectomy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bilateral discopexy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 9
Study: 27010626

Group type: EXPERIMENTAL
Intervention: Surgical reconstruction of facial defects
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Repair of a de novo small peripheral defect
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Repair of a large defect
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Repair of a central defect
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Willingness to pay per quality-adjusted life-year (WTP/QALY) for small peripheral defects
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Willingness to pay per quality-adjusted life-year (WTP/QALY) for large central defects
Number of subjects: 200
Study: 24068617

Group type: EXPERIMENTAL
Intervention: Lapband®
Number of subjects: 180

Group type: COMPARATOR
Intervention: SAGB®
Number of subjects: 180
Study: 22209175

Group type: EXPERIMENTAL
Intervention: Head down at 10° first and then 10° up and tilted right laterally during PAC placement (study group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Supine position during pulmonary artery catheterization (control group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 140
Study: 19444821

Group type: EXPERIMENTAL
Intervention: CYSTUS052 lozenges
Number of subjects: 300

Group type: COMPARATOR
Intervention: Green tea extract
Number of subjects: 300
Study: 18971153

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 45

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 45
Study: 15855656

Group type: EXPERIMENTAL
Intervention: l-homocysteine (65.1 micromol/kg body wt)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15514571

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study: 11406741

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 9262275

Group type: COMPARATOR
Intervention: Long-term pituitary desensitization followed by gonadotrophin therapy, oocyte retrieval and embryo transfer (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian electrocautery after pituitary desensitization followed by gonadotrophin therapy, oocyte retrieval and embryo transfer (group 2)
Number of subjects: 50
Study: 8328096

Group type: EXPERIMENTAL
Intervention: EMLA cream (25 mg lidocaine and 25 mg prilocaine per gram of cream)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 118
Study: 3555030

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg twice daily)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Ampicillin (500 mg four times daily)
Number of subjects: 87
Study: 29329587

Group type: EXPERIMENTAL
Intervention: Web 2.0 intervention
Number of subjects: 504

Group type: COMPARATOR
Intervention: Web 1.0 intervention
Number of subjects: 504

Group type: COMPARATOR
Intervention: Logbook intervention
Number of subjects: 504
Study: 26547399

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (30-45 seconds)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) (<10 seconds)
Number of subjects: 208
Study: 24622429

Group type: EXPERIMENTAL
Intervention: FIREHAWK stent
Number of subjects: 730
Study: 23778526

Group type: EXPERIMENTAL
Intervention: Elevated neutrophil counts
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Elevated platelet counts
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: High neutrophil-lymphocyte ratio
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: New prognostic classification incorporating inflammatory markers
Number of subjects: 362
Study: 20489194

Group type: EXPERIMENTAL
Intervention: Emerging therapeutic modalities targeting various mechanisms for neuropathic pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unbiased evaluation of neurobiological mechanisms in individual patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomewide association studies and discovery science approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of sophisticated tools for measuring neuropathic pain
Number of subjects: 0
Study: 18983546

Group type: EXPERIMENTAL
Intervention: Tecnis Z9001 IOLs
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Akreos AO IOLs
Number of subjects: 196

Group type: COMPARATOR
Intervention: KS-1 IOLs
Number of subjects: 196